21 – 30 of 655
      - show: 10
- |
- sort: year (new to old)
        Close
        
            
    
    Embed this list
<iframe src=""
              width=""
              height=""
              allowtransparency="true"
              frameborder="0">
            </iframe>
        - 2024
- 
                        Mark
        Recombinant FVIII replacement products for haemophilia A : An updated valuation by indirect comparison measuring area under the curve
    
    - Contribution to journal › Debate/Note/Editorial
 
- 
                        Mark
        Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8) : a prospective, multicentre, open-label, randomised, phase 3a trial
    
    - Contribution to journal › Article
 
- 
                        Mark
        Nonneutralizing antibodies in Nordic persons with moderate hemophilia A and B (the MoHem study)
    
    - Contribution to journal › Article
 
- 
                        Mark
        Tissue factor (F3) gene variants and thrombotic risk among middle-aged and older adults : A population-based cohort study
    
    - Contribution to journal › Article
 
- 
                        Mark
        Future needs for continuing innovation in hemophilia : improving outcomes for individuals of all severities, including women and those in resource-constrained regions
    
    - Contribution to journal › Scientific review
 
- 
                        Mark
        Historical perspective on von Willebrand disease
    (2024) p.1-6- Chapter in Book/Report/Conference proceeding › Book chapter
 
- 
                        Mark
        Textbook of von Willebrand Disease : Basic and Clinical Aspects
    
    - Book/Report › Anthology (editor)
 
- 
                        Mark
        Health-related quality of life and physical activity in Nordic patients with moderate haemophilia A and B (the MoHem study)
    
    - Contribution to journal › Article
 
- 
                        Mark
        Comparative clinical efficacy and safety of biosimilar ABP 959 and eculizumab reference product in patients with paroxysmal nocturnal hemoglobinuria
    
    - Contribution to journal › Article
 
- 
                        Mark
        Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B.
    
    - Contribution to journal › Article
 
